Met Life Investment Management, LLC Crinetics Pharmaceuticals, Inc. Transaction History

Met Life Investment Management, LLC

  • $18.1 Billion
  • Q1 2025

A detailed history of Met Life Investment Management, LLC transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 53,414 shares of CRNX stock, worth $1.6 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
53,414
Previous 53,020 0.74%
Holding current value
$1.6 Million
Previous $2.71 Million 33.91%
% of portfolio
0.01%
Previous 0.02%

Shares

42 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025
BUY
$32.3 - $53.15 $12,726 - $20,941
394 Added 0.74%
53,414 $1.79 Million
Q4 2024

Feb 13, 2025
BUY
$50.66 - $60.69 $409,586 - $490,678
8,085 Added 17.99%
53,020 $2.71 Million
Q2 2024

Aug 13, 2024
BUY
$42.12 - $51.91 $459,781 - $566,649
10,916 Added 32.09%
44,935 $2.01 Million
Q1 2024

May 14, 2024
BUY
$34.76 - $46.81 $1.18 Million - $1.59 Million
34,019 New
34,019 $1.59 Million
Q3 2023

May 09, 2024
BUY
$15.97 - $30.59 $95,372 - $182,683
5,972 Added 21.29%
34,019 $1.01 Million
Q3 2023

Apr 29, 2024
BUY
$15.97 - $30.59 $95,372 - $182,683
5,972 Added 21.29%
34,019 $1.01 Million
Q3 2023

Nov 14, 2023
BUY
$15.97 - $30.59 $95,372 - $182,683
5,972 Added 21.29%
34,019 $1.01 Million
Q2 2023

Apr 29, 2024
BUY
$15.73 - $23.6 $441,179 - $661,909
28,047 New
28,047 $505,000
Q1 2023

May 09, 2024
BUY
$15.31 - $21.1 $429,399 - $591,791
28,047 New
28,047 $450 Million
Q4 2022

May 10, 2024
BUY
$15.49 - $19.05 $12,268 - $15,087
792 Added 2.91%
28,047 $513,000
Q4 2022

Mar 22, 2023
BUY
$15.49 - $19.05 $12,268 - $15,087
792 Added 2.91%
28,047 $513,000
Q4 2022

Feb 15, 2023
BUY
$15.49 - $19.05 $12,268 - $15,087
792 Added 2.91%
28,047 $513,000
Q3 2022

May 10, 2024
BUY
$18.11 - $22.37 $33,286 - $41,116
1,838 Added 7.23%
27,255 $535,000
Q3 2022

Jun 14, 2023
SELL
$18.11 - $22.37 $14,343 - $17,717
-792 Reduced 2.82%
27,255 $535,000
Q3 2022

Mar 22, 2023
BUY
$18.11 - $22.37 $33,286 - $41,116
1,838 Added 7.23%
27,255 $535,000
Q3 2022

Nov 14, 2022
BUY
$18.11 - $22.37 $33,286 - $41,116
1,838 Added 7.23%
27,255 $535,000
Q2 2022

Jun 20, 2023
SELL
$16.49 - $27.64 $43,368 - $72,693
-2,630 Reduced 9.38%
25,417 $474,000
Q1 2022

May 10, 2024
BUY
$17.15 - $28.31 $435,901 - $719,555
25,417 New
25,417 $557,000
Q1 2022

Jun 20, 2023
SELL
$17.15 - $28.31 $45,104 - $74,455
-2,630 Reduced 9.38%
25,417 $557,000
Q1 2022

Mar 22, 2023
BUY
$17.15 - $28.31 $155,430 - $256,573
9,063 Added 55.42%
25,417 $557,000
Q1 2022

May 12, 2022
BUY
$17.15 - $28.31 $155,430 - $256,573
9,063 Added 55.42%
25,417 $558,000
Q4 2021

May 17, 2024
BUY
$19.35 - $28.41 $91,061 - $133,697
4,706 Added 40.4%
16,354 $464,000
Q4 2021

Jun 21, 2023
SELL
$19.35 - $28.41 $226,259 - $332,198
-11,693 Reduced 41.69%
16,354 $464,000
Q4 2021

Mar 22, 2023
BUY
$19.35 - $28.41 $91,061 - $133,697
4,706 Added 40.4%
16,354 $464,000
Q4 2021

Feb 15, 2022
BUY
$19.35 - $28.41 $91,061 - $133,697
4,706 Added 40.4%
16,354 $465,000
Q3 2021

Jun 21, 2023
SELL
$16.88 - $25.23 $276,815 - $413,746
-16,399 Reduced 58.47%
11,648 $245,000
Q2 2021

Jun 21, 2023
SELL
$15.9 - $21.15 $260,744 - $346,838
-16,399 Reduced 58.47%
11,648 $219,000
Q1 2021

May 17, 2024
SELL
$13.3 - $17.55 $297,534 - $392,611
-22,371 Reduced 65.76%
11,648 $177,000
Q1 2021

Jun 26, 2023
SELL
$13.3 - $17.55 $218,106 - $287,802
-16,399 Reduced 58.47%
11,648 $178 Million
Q1 2021

Mar 22, 2023
SELL
$13.3 - $17.55 $14,417 - $19,024
-1,084 Reduced 8.51%
11,648 $177,000
Q1 2021

May 14, 2021
SELL
$13.3 - $17.55 $14,417 - $19,024
-1,084 Reduced 8.51%
11,648 $178,000
Q4 2020

Jun 22, 2023
SELL
$12.08 - $17.46 $185,005 - $267,399
-15,315 Reduced 54.6%
12,732 $179,000
Q3 2020

Jun 26, 2023
SELL
$13.62 - $17.66 $208,590 - $270,462
-15,315 Reduced 54.6%
12,732 $199,000
Q2 2020

May 24, 2024
SELL
$13.04 - $23.23 $277,582 - $494,497
-21,287 Reduced 62.57%
12,732 $223 Million
Q2 2020

Jun 26, 2023
SELL
$13.04 - $23.23 $199,707 - $355,767
-15,315 Reduced 54.6%
12,732 $223,000
Q2 2020

Mar 22, 2023
BUY
$13.04 - $23.23 $89,936 - $160,217
6,897 Added 118.2%
12,732 $223,000
Q2 2020

Aug 14, 2020
BUY
$13.04 - $23.23 $89,936 - $160,217
6,897 Added 118.2%
12,732 $223,000
Q1 2020

Jul 12, 2023
SELL
$11.52 - $26.46 $255,882 - $587,729
-22,212 Reduced 79.2%
5,835 $85,000
Q4 2019

Jul 12, 2023
SELL
$15.24 - $25.09 $338,510 - $557,299
-22,212 Reduced 79.2%
5,835 $146,000
Q4 2019

Mar 22, 2023
SELL
$15.24 - $25.09 $338,510 - $557,299
-22,212 Reduced 79.2%
5,835 $146,000
Q4 2019

Feb 14, 2020
BUY
$15.24 - $25.09 $88,925 - $146,400
5,835 New
5,835 $146,000
Q2 2019

Jul 12, 2023
SELL
$21.48 - $27.71 $476,533 - $614,746
-22,185 Reduced 79.1%
5,862 $147 Million

Others Institutions Holding CRNX

# of Institutions
235
Shares Held
87M
Call Options Held
40K
Put Options Held
162K
View Full List

About Crinetics Pharmaceuticals, Inc.

CRNX Quotes by TradingView
  • Ticker CRNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 53,752,800
  • Market Cap $1.61B
  • Description
  • Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...
More about CRNX
Track This Portfolio

Track Met Life Investment Management, LLC Portfolio

Follow Met Life Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Met Life Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Met Life Investment Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email